RACHEL BAKER: Open Payments
NPI 1851665624 · BELLEVUE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,325 in 13 payments from 8 companies in 2025. Trend: 2023 $274 · 2024 $877 · 2025 $1,325
Food & beverage: $1,325
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $361 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $242 |
| Alkermes, Inc. | 2 | $238 |
| E.R. Squibb & Sons, L.L.C. | 2 | $195 |
| Axsome Therapeutics, Inc. | 1 | $117 |
| Tris Pharma Inc | 1 | $113 |
| Abbott Laboratories | 1 | $38 |
| Novo Nordisk Inc | 1 | $21 |
Products named: INGREZZA, CAPLYTA, COBENFY, LYBALVI, Auvelity, ARISTADA, Dyanavel XR, MITRACLIP.
Industry payments across WA — which companies pay providers there.
